Towards a novel treatment strategy for acute pancreatitis: Principles and potential practice

Digestion

Volumn 63, Issue 3, 2001, Pages 143-162

  Braganza, Joan M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adrenergic agonist; Acute pancreatitis treatment; Anaphylactoid reaction; Ascorbate; Contact system; EpiPen; Heparin; Oxidative stress; Trypsinogen dipstick test

Indexed keywords

ACUTE PANCREATITIS; HUMAN; IMMUNE RESPONSE; MAST CELL; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EMERGENCY TREATMENT; FEMALE; HUMANS; MALE; PANCREATITIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS;

EID: 0035001865     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051884     Document Type: Review

References (174)

1. Braganza JM: Towards a novel treatment strategy for acute pancreatitis. 1. Reappraisal of the evidence on aetiogenesis. Digestion 2001;63: 69-91.
2. Braganza JM: Mast cell: Pivotal player in lethal acute pancreatitis. Q J Med 2000;93:469-476.
3. Innerfield I, Angrista A, Benjamin JW: Antithrombin titre in acute pancreatitis. Am J Med 1952;12:24-33.
4. Las Heras G, Roncalés FJ, Juncà J, Gener J: La antitrombina-III: Su valor pronóstico en las pancreatitis agudas. SANGRE 1992;37:165-168.
5. Dervenis C, Bassi C: Evidence-based assessment of severity and management of acute pancreatitis. Br J Surg 2000;87:257-258.
6. Ranson JHC, Lackner H, Herman IR, Schinella R: The relationship of coagulation factors to clinical complications of acute pancreatitis. Surgery 1977;81:502-511.
7. Berry AR, Taylor TV, Davies GC: Pulmonary function and fibrinogen metabolism in acute pancreatitis. Br J Surg 1981;68:870-873.
8. Hasegawa N, Husari AW, Hart WT, Kandra TG, Raffin TA: Role of the coagulation system in ARDS. Chest 1994;105:268-277.
9. Imrie CW, McKay CJ: The scientific basis of medical therapy of acute pancreatitis. Gastroenterol Clin N Am 1999;28:591-599.
10. John K, Chaloner C, Hassan H, Appelros S, Borgström A, Blann A, Segal I, Braganza JM: Studies towards interpretation of trypsinogen activation in acute pancreatitis. Proceedings of the Pancreatic Society of Great Britain and Ireland, London November 1999 (abstract). Int J Pancreatol 2000:27:271.
11. Colman RW, Schmaier AH: Contact system: A vascular biology modulator with profibrinolytic, antiadhesive, and pro-inflammatory attributes. Blood 1997;90:3819-3843.
12. Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaler AD, Colman RW: Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988;112:270-277.
13. Birk D, Poch B, Schoenberg MH, Markgraf A, Beger HG: ERCP induces the formation of oxygen free radicals (abstract). Digestion 1997; 58(suppl 2):26.
14. Messman H, Vogt W, Holstege A, Lock G, Henisch A, von Furstenberg A, Leser HG, Zirngibl H, Scholmerich J: Post-ERCP pancreatitis as a model for cytokinc induced acute phase response in acute pancreatitis. Gut 1997; 40:80-85.
15. Oczcueruemez-Porsch M, Kunz D, Hurdt PD, Fadgyas T, Kress O, Schulz HU, Schnell-Kretschmer H, Temme H, Westphal S, Luley C, Kloer HU: Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. Dig Dis Sci 1998;43:1763-1769.
16. 1 antitrypsin complex values identify endoscopic retrograde cholangiopancreatography induced pancreatitis with high accuracy. Gut 1997;41:690-695.
17. Banks PA, Carr-Locke DL, Slivka A, Van Dam J, Lichtenstein DR, Hughes M: Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis. Pancreas 1996;12:294-297.
18. Petersson U, Appelros S, Ohlsson K, Borgström A: Is activation of the pancreatic enzymes an important pathophysiological mechanism in ERCP induced pancreatitis (abstract). Pancreas 1998;17:452.
19. Appelros S, Tim L, Borström A: Activation peptide of procarboxypeptidase B in serum and urine in acute pancreatitis. Gut 1998;42:97-102.
20. Dolan SJ, Lewis H, McCluggage G, Halliday MI, Rowlands BJ: Systemic endotoxin, antiendotoxin antibodies and proinflammatory cytokines in the taurocholate model of acute pancreatitis. HPB 1999;1:71-77.
21. Zhang Y, Ramos BF, Jakschik BA: Neutrophil recruitment by tumour necrosis factor from mast cells in immune complex peritonitis. Science 1992;258:1957-1959.
22. Kemppainen E, Hedstrom J, Puolakkainen P, Halttunen J, Sainio V, Haapiainen R, Stenman U-H: Urinary trypsinogen-2 test strip in detecting ERCP-induced pancreatitis. Endoscopy 1997;29:247-251.
23. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V, and the Gabexate in Digestive Endoscopy-Italian Group: Gabexate tor the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996;335:919-923.
24. Rabenstein T, Framke B, Martus P, Ell C, Hahn EG, Schneider HT: Prevention of post-ERCP pancreatitis (AP) by heparin: A prospective study with respect to risk factors (RF) for AP. Gastroenterology 1999:6(suppl 4):A1157.
25. Adler G, Rausch U, Weidenbach F, Arnold R, Kern HF: General and selective inhibition of pancreatic enzyme discharge using a proteinase inhibitor (FOY-305). Klin Wochenschr 1984; 62:406-411.
26. Singh VP, Saluja AK, Bhagat L, Hietaranta A, Song A, Akella U, Pan A, Steer ML: Serine proteases regulate exocytosis and F-actin distribution in rat pancreatic acinar cells (abstract). Gastroenterology 2000;118:A1155.
27. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP: Heparin in inflammation: Potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151-208.
28. Hiebert L, Lin JM: Protective action of polyelectrolytes on endothelium. Semin Thromb Hemost 1991;17(suppl 1):42-46.
29. Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacob HS: Tumour necrosis factor alpha/cachectin stimulates cosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990;171:2025-2041.
30. Dominguez-Munoz, Carballo F, Garcia MJ, de Diego JM, Rabago L, Simon MA, de la Morena J: Clinical usefulness of polymorphonuclear elastase in predicting the severity of acute pancreatitis: Results of a multicentre study. Br J Surg 1991;78:1230-1234.
31. Kuklinski B, Zimmermann T, Schweder R: Decreasing mortality in acute pancreatitis with sodium selenite. Clinical results of 4 years antioxidant therapy (in German). Med Klin 1995; 90(suppl 1):36-41.
32. Neoptolemos JP, Kemppainen EA, Mayer JM, Fitzpatrick JM, Raraty MGT, Slavin J, Beger HG, Hietaranta AJ, Puolakkainen PA: Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: A multicentre study. Lancet 2000;355:1955-1960.
33. Sharer NM, Scott PD, Deardon DJ, Lee SH, Taylor PM, Braganza JM: Clinical trial of 24 hours' treatment with glutathione precursors in acute pancreatitis. Clin Drug Invest 1995;10: 147-157.
34. Braganza JM, Scott P, Bilton D, Schofield D, Chaloner C, Shiel N, Hunt LP, Bottiglieri T: Evidence for early oxidative stress in acute pancreatitis: Clues for correction. Int J Pancreatol 1995;17:69-81.
35. Tsai K, Wang SS, Chen TS, Kong CW, Chang FY, Lee SD, Lu FJ: Oxidative stress: An important phenomenon with pathogenic significance in the progression of acute pancreatitis. Gut 1998;42:850-855.
36. Schulz, H-U, Niederau C, Klonowski-Stumpe H, Halangk W, Luthen R, Lipper H: Oxidative stress in acute pancreatitis. Hepato-Gastroenterology 1999;46:2736-2750.
37. Bonham MJD, Abu-Zidan FM, Simovic MO, Sluis KB, Wilkinson A, Winterbourn CC, Windsor JA: Early ascorbic acid depletion is related to the severity of acute pancreatitis. Br J Surg 1999;86:1296-1301.
38. Tenner S, Fernandez del-Castillo C, Warshaw A, Steinberg W, Hermon-Taylor J, Valenzuela JE, Hariri M, Hughes M, Banks PA: Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. Int J Pancreatol 1997;21:105-10.
39. Gudgeon AA, Heath DI, Hurley P, Jehanli A, Patel G, Wilson C, Shenkin A, Austin BM, Imrie CW, Hermon-Taylor J: Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 1990:i: 4-6.
40. 2) and plasma polymorphonuclear elastase (PMN-E) in different-severity forms of human AP. Pancreas 1998;17:163-168.
41. Ranson JHC: Etiological and prognostic factors in human acute pancreatitis: A review. Am J Gastroenterol 1982;77:633-638.
42. Bank S, Wise L, Gersten M: Risk factors in acute pancreatitis. Am J Gastroenterol 1983; 78:637-640.
43. Cavallini G, Di Francesco B, Bovo P, Frulloni L: Antiproteases: New aspects of treatment; in Büchler MW, Uhl W, Friess H, Malfertheiner P (eds): Acute Pancreatitis, Novel Concepts in Biology and Medicine. Berlin, Blackwell Science, 1999, pp 299-306.
44. Norman J: The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998; 175:76-83.
45. Norman JG: New approaches to acute pancreatitis: Role of inflammatory mediators. Digestion 1999;60(suppl 1):57-60.
46. Glazer G, Mann DV: United Kingdom guidelines for the management of acute pancreatitis. Gut 1998;24(suppl 2):S1-S13.
47. Bradley EL: Necrotizing pancreatitis. Br J Surg 1999;86:147-148.
48. Mayer J, Rau B, Shoenberg MH, Beger HG: Mechanism and role of trypsinogen activation in acute pancreatitis. Hepatogastroenterology 1999;46:2757-2763.
49. Thal AP, Perry JF, Egner W: A clinical and morphologic study of forty-two cases of fatal acute pancreatitis. Surg Gynecol Obstet 1957; 105:191-201.
50. Kylänpää-Bäck M-L, Kemppainen E, Puolakkainen P, Hedström J, Haapiainen R, Perhoniemi V, Kivilaakso E, Korvuo A, Stenman U-H: Reliable screening for acute pancreatitis with rapid urine trypsinogen-2 test strip. Br J Surg 2000;87:49-52.
51. Galen RS, Gambino SR: Beyond Normality. London, Wiley, 1975.
52. Edwards AWF: Likelihood. Cambridge, Cambridge University Press, 1972.
53. Jaeschke R, Guyatt GH, Sackett DL: Users' guides to medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 1994;271:703-707.
54. Braganza JM: Does your patient have pancreatic disease? J R Coll Phys Lond 1981;16: 13-22.
55. Windsor J: Search for prognostic markers for acute pancreatitis. Lancet 2000;355:1924-1925.
56. McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW: Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997;84:1239-1243.
57. Kingsnorth AN, Galloway SW, Formela LJ: Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-1420.
58. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999;340: 207-214.
59. Martinez J, Sánchez-Payá J, Palazón JM, Aparico JR, Picó A, Pérez-Mateo M: Obesity: A prognostic factor of severity in acute pancreatitis. Pancreas 1999;19:15-20.
60. Brown A, Orav J, Banks PA: Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis. Pancreas 2000;20: 367-372.
61. Petersson U, Appelros S, Borgström A: Different patterns in immunoreactive anionic and cationic trypsinogen in urine and serum in human acute pancreatitis. Int J Pancreatol 1999;25:165-170.
62. Bonham MJD, Abu-Zidan FM. Simovic MO, Windsor JA: Gastric intramucosal pH predicts death in severe acute pancreatitis. Br J Surg 1997;84:1670-1674.
63. Soong CV, Lewis HG, Halliday I, Rowlands BJ: Intramucosal acidosis and the inflammatory response in acute pancreatitis. Am J Gastroenterol 1999;94:2423-2429.
64. Juvonen PO, Alhava EM, Takala JA: Gastric tonometry in assessing splanchnic tissue perfusion in acute pancreatitis. Scand J Gastroenterol 2000;3:318-321.
65. Hynninen M, Valtonen M, Markkanen H, Vaara M, Kuusela R, Jousela I, Piilonen A, Takkunen O: Intramucosal pH and endotoxin and cytokine release in severe acute pancreatitis. Shock 2000;13:79-82.
66. Sandoval D, Gukovskaya A, Reavey P, Gukovsky S, Sisk A, Braquet P, Pandol SJ, Poucell-Hatton S: The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 1996; 111:1081-1091.
67. De Sanctis JT, Lee MJ, Gazelle GS, Boland GW, Halpern EF, Saini S, Mueller PR: Prognostic indicators in acute pancreatitis: CT vs APACHE II. Clin Radiol 1997;52:842-848.
68. Tenner S, Sica G, Hughes M, Noordhoek E, Feng S, Zinner M, Banks PA: Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997;113:899-903.
69. 2 in relation to systemic inflammatory response syndrome (SIRS) and systemic complications in severe acute pancreatitis. Pancreas 1999;18:385-391.
70. Ewan PW: Anaphylaxis. Br Med J 1998;316: 1442-1445.
71. Holgate ST, Church MK (eds): Allergy. London, Gower Medical Publishing, 1993.
72. Altenburg SP, Martins MA, Silva PMR, Bozza PT, Tibirica EV, Cordeiro RSB, Castro-Faria-Neto HC: Systemic neutrophilia observed during anaphylactic shock in rats is inhibited by dopaminergic antagonists. Int Arch Allergy Immunol 1995;108:33-38.
73. Steer ML, Meldolesi J: The cell biology of experimental pancreatitis. N Engl J Med 1987; 316:144-150.
74. Nonaka A, Manabe T, Tobe T: Effect of a new synthetic ascorbic acid derivative, as a free radical scavenger, on the development of acute pancreatitis in mice. Gut 1991;32:528-532.
75. Mannaioni PF, Masini E: The release of histamine by free radicals. Free Radic Biol Med 1988;5:177-197.
76. Di Bello MG, Masini E, Ioannides C, Fomusa Ndisang J, Raspanti S, Bani Sacchi T, Mannaioni PF: Histamine release from rat mast cells induced by the metabolic activation of drugs of abuse into free radicals. Inflamm Res 1998;47:122-130.
77. Wolfreys K, Oliveira DB: Alterations in intracellular reactive oxygen species generation and redox potential modulate mast cell function. Eur J Immunol 1997;27:297-306.
78. Ortner MJ: The oxidation of endogenous ascorbic acid during histamine secretion by rat peritoneal mast cells. Exp Cell Res 1980;129:485-487.
79. Subramanian N: Histamine degradative potential of ascorbic acid: Considerations and evaluations. Agents Actions 1978;8:484-487.
80. Reber A, Adler G, Karanjia N, Widdison A: Permeability characteristics of the main pancreatic duct in cats: Models of acute and chronic pancreatitis: in Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA (eds): The Pancreas: Biology, Pathobiology, and Disease, ed 2. New York, Raven Press, 1993, pp 527-550.
81. Harvey MH, Wedgwood KR, Reber HA: Treatment of acute pancreatitis with β-adrenergic agonist drugs. Surgery 1987;102:229-234.
82. Karanjia ND, Widdison AL, Reber HA: Dopamine in models of alcoholic acute pancreatitis. Gut 1994;35:547-551.
83. Assem ESR, Schild HO: Inhibition by sympathomimetic amines of histamine release induced by antigen in passively sensitized human lung. Nature 1969;224:1028-1029.
84. Ohuchi K, Watanabe M, Hirasawa N, Yoshizaki S, Mue S, Tsurufuji S: Suppression by adrenoceptor beta-agonists of vascular permeability increase and edema formation induced by arachidonate metabolites, platelet-activating factor, and tumour-promoting phorbol ester TPA. Immunopharmacology 1990;20:81-88.
85. Hotbauer B, Saluja AK, Bhatia M, Frossard J-L, Lee H-S, Bhagat L, Steer ML: Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology 1998;115: 1238-1247.
86. Formela LJ, Wood LM, Whittaker M, Kingsnorth AN: Amelioration of acute pancreatitis in a rat model by a potent platelet activating factor antagonist. Br J Surg 1994;81:1783-1785.
87. Lawrence DA, Loskutoff DJ: Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry 1986;25:6351-6355.
88. Myers AK, Nakanishi T, Ramwell P: Antagonists of PAF-induced death in mice. Prostaglandins 1988;35:447-458.
89. Murphy RC: Free radical-induced oxidation of glycerophosphocholine lipids and formation of biologically active products: in Nigam S, Kunkel G, Prescott SM (eds): Platelet-Activating Factor and Related Lipid Mediators 2. New York, Plenum Press, 1996, pp 51-58.
90. Goodhead B, Wright PW: The effect of postganglionic sympathectomy on the development of hemorrhagic pancreatitis in the dog. Ann Surg 1969;170:951-960.
91. Davies RM, Moore FT, Wynn-Williams D: Treatment of acute pancreatitis with hexamethonium bromide. Br Med J 1953;5:1251-1252.
92. Popper HL: Acute pancreatitis. An evaluation of the classification, symptomatology, diagnosis and therapy. Am J Dig Dis 1948;15:1-4.
93. Gage M, Gillespie G: Acute pancreatitis and its treatment. South Med J 1951;44:769-774.
94. Dale WA, Rochester NY: Splanchnic block in the treatment of acute pancreatitis. Surgery 1952;32:605-614.
95. Wright PW, Goodhead B: Prevention of hemorrhagic pancreatitis with fibrinolysin or heparin. Arch Surg 1970;100:42-46.
96. Wright PW, Goodhead B: The value of dextrans in the treatment of experimental pancreatitis. Surgery 1970;67:807-815.
97. Donaldson LA, Schenk WG: Experimental acute pancreatitis: The changes in pancreatic oxygen consumption and the effect of dextran 40. Ann Surg 1979;190:728-731.
98. Baram D, Rashkovsky M, Hershkoviz I, Drucker I, Reshef T, Ben-Shitrit S, Mekori YA: Inhibitory effects of low molecular weight heparin on mediator release by mast cells: Preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. Clin Exp Immunol 1997;110: 485-491.
99. Project Team of the Resuscitation Council (UK). The emergency medical treatment of anaphylactic reactions. J Accid Emerg Med 1999;16:243-247.
100. Knoefel WT, Kollias N, Warshaw AL, Waldner H, Nishioka NS, Rattner DW: Pancreatic microcirculalory changes in experimental pancreatitis of graded severity in the rat. Surgery 1994;116:904-913.
101. Navarro L, Wilk P, Rudick J, Dreiling DA: The effect of isuprel on experimentally-induced pancreatitis in the dog. Am J Gastroenterol 1974;61:387-389.
102. Araida T, Frey CF, Ruebner B, Carlson J, King J: Therapeutic regimens in acute experimental pancreatitis in rats: Effects of a protease inhibitor, a β-agonist, and antibiotics. Pancreas 1995;11:132-140.
103. Acalovschi I, Balescu A, Bacanu D, Gioroceanu A, Ban A, Toader S: The protective effects of alpha and beta adrenergic receptors blockaders in the experimental acute pancreatitis of rats (in Rumanian). Rev Chir Oncol Radiol ORL Oftalmol Stomatol Chir 1984; 33:387-393.
104. Acalovschi I, Turdeanu N, Bontidean A: Effectiveness of the sympatho-adrenergic blocking in the prophylaxis of acute postoperative pancreatitis (in Rumanian). Rev Chir Oncol Radiol ORL Oftalmol Stomatol Chir 1980; 29:25-28.
105. Weidenbach H, Lerch MM, Gress TM, Pfaff D, Turi S, Adler G: Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis. Gut 1995;37:434-440.
106. Lechin F, van der Dijs B, Lechin M, Jara H, Lechin A, Cabrera A, Rada I, Orozco B, Jimenez V, Valderrama T: Dramatic improvement with clonidine in acute pancreatitis with elevated catecholamine and cortisol plasma levels: Report of five cases. J Med 1992;23:119-351.
107. Vaysse N, Bastie MK, Pascal JP, Martinel C, Fourtanier G, Ribet A: Effects of catecholamines and their inhibitors on the isolated canine pancreas. Gastroenterology 1977;72: 711-718.
108. Rudick J, Gonda M, Rosenberg IR, Chapman ML, Dreiling DA, Janowitz HD: Effects of beta-adrenergic receptor stimulant (isoproterenol) on pancreatic exocrine secretion. Surgery 1973;74:338-343.
109. Pederson R, Schulz I: The effect of isoproterenol on enzyme secretion from the isolated perfused cat pancreas. Biochim Biophys Acta 1974;338:440-446.
110. Barnes PJ: Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998;94:557-572.
111. Powell JJ, Fearon KCH, Siriwardena AK: Current concepts of the pathophysiology and treatment of severe acute pancreatitis. Br J Intens Care 2000;10:51-59.
112. Van Voorthuizen T, Helmers JH, Tjoeng MM, Otten MH: Meperidine(pethidine) outdated against pain in acute pancreatitis (in Dutch, English abstract). Ned Tijdschr Geneeskd 2000;144:656-658.
113. Paton WDM: The paralysis of autonomic ganglia, with special reference to the therapeutic effects of ganglion-blocking drugs. Br Med J 1951;14:773-778.
114. Donaldson LA, Joffe SN, Schenk WG: Acute pancreatitis - ischaemia or hyperaemia? Med Hypotheses 1980;6:329-336.
115. Benz S, Pfeffer F, Adam U, Schareck W, Hopt UT: Impairment of pancreatic microcirculation in the early reperfusion period during simultaneous pancreas-kidney transplantation. Transplant Int 1998;11(suppl 1):S433-S435.
116. Sanfey H, Cameron JL: Increased capillary permeability: An early lesion in acute pancreatitis. Surgery 1984;96:485-491.
117. Barr ML, Carey JN, Nishanian GP, Roberts RF, Sakamaki Y, Darbinian SH, Starnes VA: Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg 1998;115:631-637.
118. Klar E, Messmer K, Warshaw AL, Herfarth C: Pancreatic ischaemia in experimental acute pancreatitis: Mechanism, significance and therapy. Br J Surg 1990;77:1205-1210.
119. Gillbe CE, Sage FJ, Gutteridge JMC: Commentary: Mannitol: molecule magnifique or a case of radical misinterpretation? Free Radic Res 1996;24:1-7.
120. Sharer NM, Taylor PM, Lineker BD, Gutteridge JMC, Braganza JM: Safe and successful use of vitamin C to treat painful calcific chronic pancreatitis despite iron overload from primary haemochromatosis. Clin Drug Invest 1995;10:310-315.
121. Braganza JM, Holmes AM, Morton AR, Stalley L, Ku R, Kishen R: Acetylcysteine to treat complications of pancreatitis. Lancet 1986;i: 914-915.
122. Braganza JM: Antioxidant therapy for pancreatitis: Clinical experience; in Braganza JM (ed): The Pathogenesis of Pancreatitis. Manchester, Manchester University Press, 1991, pp 178-197.
123. Goode HF, Webster N: Free radicals and antioxidants in sepsis. Crit Care Med 1993; 21:1770-1776.
124. Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J-M, Suter PM: Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996;24:392-397.
125. Frei B, Stocker R, England L, Ames BN: Ascorbate: The most effective antioxidant in human blood plasma; in Emerit I, Packer L, Auclair C (eds): Antioxidants in Therapy and Preventive Medicine, New York, Plenum Press, 1990, pp 155-163.
126. Halliwell B: How to characterize a biological antioxidant. Free Rad Res Commun 1990;9: 1-32.
127. Feigen GA, Smith BH, Dix CE, Flynn CJ, Peterson NS, Rosenberg LT, Pavlovic S, Leibovitz B: Enhancement of antibody production and protection against systemic anaphylaxis by large doses of vitamin C. Res Commun Chem Pathol Pharmacol 1982;38:313-333.
128. Pavlovic S, Fraser R: Effects of different levels of vitamin C intake on the vitamin C concentration in guinea pigs plasma and the effect of vitamin C on anaphylaxis. Med Interne 1988;26:235-244.
129. Bernard C: Mémoiré sur le pancréas. Paris, Ballière, 1856.
130. Thal AP, Kobold EE, Hollenberg MJ: The release of vasoactive substances in acute pancreatitis. Am J Surg 1963;105:708-713.
131. Shimizu J, Wada S, Okhisa T, Kamimura M, Yano M, Kodira T, Nishino T, Schima K, Ito S: Radioimmunoreactive plasma bradykinin levels and histological changes during the course of caerulein-induced pancreatitis in rats. Pancreas 1993;8:220-225.
132. Glazer G, Bennett A: Prostaglandin release in canine acute haemorrhagic pancreatitis. Gut 1976;17:22-26.
133. Huang ZL, Mochizuki T, Watanabe H, Kagoshima M, Maeyama K: Biphasic elevation of plasma histamine induced by water immersion stress, and their sources in rats. Eur J Pharmacol 1998;360:139-146.
134. 2)-production from histamine. Ann Anat 1995;177:431-438.
135. Schofield D, Sharer NM, Heywood KM, Waters HM, Braganza JM: Blood glutathione and folate in acute pancreatitis (abstract). Int J Pancreatol 1994;16:321.
136. Schofield D, Summan M, Shiel N, Sharer NM, Braganza JM: Blood glutathione and adenylates in acute pancreatitis. Biochem Soc Trans 1993;21:4505.
137. Dass PD, Bermes EW, Holmes EW: Renal and hepatic output of glutathione in plasma and whole blood. Biochim Biophys Acta 1992;1156:99-102.
138. Mendiratta S, Qu ZC, May JM: Erythrocyte ascorbate recycling: Antioxidant effects in blood. Free Rad Biol Med 1998;24:789-797.
139. Foitzik T, Stufler M, Hotz HG, Klinnert J, Wagner J, Warshaw AL, Schulzke JD, Fromm M, Buhr HJ: Glutamine stabilizes intestinal permeability and reduces pancreatic infection in acute experimental pancreatitis. J Gastrointest Surg 1997;1:40-47.
140. de Beaux AC, O'Riordain MG, Ross JA, Jodozi I., Carter DC, Fearon KCH: Glutamine-supplemented total parenteral nutrition reduces blood mononuclear cell interleukin-8 release in severe acute pancreatitis. Nutrition 1998;14:261-265.
141. Birk D, Schoenberg MH, Eisele S, Mbock A, Rau B, Beger HG: The role of oxygen radicals in acute pancreatitis. Clinical and experimental results of therapy with free radical scavengers (in German). Med Klin 1995:90(suppl 1): 32-35.
142. Kuklinski B, Buchner M, Müller T, Schweder R: Antioxidative therapy of pancreatitis: An 18 months' interim evaluation (in German). Z Ges Inn Med 1992;47:229-235.
143. Tehoumkeu-Nzouessa GC, Rebel G: Differential effect of ebselen on compound 48/80- and anti-IgE-induced histamine release from rat peritoneal mast cells. Biochem Pharmacol 1998;56:1525-1528.
144. Pearson DJ, Suarez-Mendez VJ, Day JP, Miller PF: Selenium status in relation to reduced glutathione peroxidase activity in aspirin-sensitive asthma. Clin Exp Allergy 1991; 21:203-208.
145. Terada A, Yoshida M, Seko Y, Kobayashi T, Yoshida K, Nakada M, Nakada K, Echizen H, Ogata H, Rikihisa T: Active oxygen species generation and cellular damage by additives of parenteral preparations: Selenium and sulfhydryl compounds. Nutrition 1999; 15:651-655.
146. Ammori BJ, Leeder PC, King RFGJ, Barclay GR, Martin IG, Larvin M, McMahon MJ: Early increase in intestinal permeability in patients with severe acute pancreatitis: Correlation with endotoxemia, organ failure, and motality. J Gastrointest Surg 1999;3:252-262.
147. Shields CJ, Winter DC, Sookhai S, Ryan L, Kirwan WO, Redmond HP: Hypertonic saline attenuates end-organ damage in an experimental model of acute pancreatitis. Br J Surg 2000;87:1336-1340.
148. Bhatia M, Brady M, Zagorski J, Christmas SE, Campbell F, Neoptolemos JP, Slavin J: Treatment with neutralising antibody against cytokine induced neutrophil chemoattractant (CINC) protects rats against acute pancreatitis associated lung injury. Gut 2000;47:838-844.
149. Powell JJ, Murchison JT, Fearon KC, Ross JA, Siriwardena AK: Randomised controlled trial of the effect of early parenteral nutrition on markers of the inflammatory response in predicted severe acute pancreatitis. Br J Surg 2000;87:1375-1381.
150. Cregar I, Elrod KC, Putnam D, Moore WR: Neutrophil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase. Arch Biochem Biophys 1999;366:125-130.
151. Piolot A, Nadler F, Cavallero E, Coquard JL, Jacotot B: Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: Value of regular plasmapheresis. Pancreas 1996;13:96-99.
152. Imrie CW, Allam BF, Ferguson JC: Hypocalcaemia of acute pancreatitis: The effect of hypoalbuminaemia. Curr Med Res Opin 1976;4:101-116.
153. Elliott DW: Treatment of acute pancreatitis with albumin and whole blood. AMA Arch Surg 1957;75:573-580.
154. Quinlan GJ, Margarson MP, Mumby S. Evans TW. Gutteridge JMC: Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion. Clin Sci 1998;95:459-465.
155. Leese T, Holliday M, Heath D, Hall AW, Bell PRF: Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg 1987;74:907-911.
156. Sigurdsson GH: Acute pancreatitis: Therapeutic options in multiple organ failure; in Büchler MW, Uhl W, Friess H, Malfertheiner P (eds): Acute Pancreatitis: Novel Concepts in Biology and Therapy. Berlin, Blackwell Science Inc, 1999, pp 395-410.
157. Dasta JF, Kirby MG: Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy 1986;6:304-310.
158. Boyd O, Grounds M, Bennett EA: Randomised clinical trial of the effect of deliberate perioperative increase of oxygen delivery in high-risk surgical patients. JAMA 1993;270: 2699-2707.
159. Segal JM, Phang PT, Walley KR: Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 1992;73:1159-1164.
160. Ruokonen R, Uusaro A, Alhava E, Takala J: The effect of dobutamine infusion on splanchnic blood flow and oxygen transport in patients with acute pancreatitis. Intens Care Med 1997;23:732-737.
161. Lockey SD: A new method of administering aqueous epinephrine: The EpiPen, an automatic syringe. J Asthma Res 1980;17:153-155.
162. Louw JH, Marks IN, Bank S: The management of severe acute pancreatitis. Postgrad Med J 1967;43:31-44.
163. Marshall JC: Descriptors of organ system dysfunction for the multiple organ dysfunction syndrome (MODS); in Vicent J-L, Sibbald WJ (eds): Clinical Trials for the Treatment of Sepsis. Berlin, Springer, 1995, pp 122-138.
164. Bernard GR: Quantification of organ dysfunction: Seeking standardization. Crit Care Med 1998;26:1767-1768.
165. Appelros S, Petersson U, Toh S, Johnson C, Borgstrom A: Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of the severity of acute pancreatitis. Br J Surg 2001;88:216-221.
166. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SKC, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD: Double blind, randomized, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62-69.
167. Satoh A, Shimosegawa T, Satoh K, Ito H, Kohno Y, Masamune A, Fujita M, Toyota T: Activation of adenosine A I-receptor pathway induces edema formation in the pancreas of rats. Gastroenterology 2000;119:829-836.
168. Erba F, Fiorucci L, Pascarella S, Menegatti E, Ascenzi P, Ascoli F: Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Biochem Pharmacol 2001;61:271-276.
169. Kylänpää-Bäck M-L. Takala A, Kemppainen E, Puolakkainen P, Haapiainen R, Repo H: Procalcitonin strip test in the early detection of severe acute pancreatitis. Br J Surg 2001; 88:222-227.
170. Mándi Y, Farkas G, Takács T, Boda K, Lonovics J: Diagnostic relevance of procalcitonin, 1L-6, and sICAM-1 in the prediction of infected necrosis in acute pancreatitis. Int J Pancreatol 2000;28:43-51.
171. Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K: Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 1999;37:789-797.
172. Vincent J-L: Procalcitonin: THE marker of sepsis? Crit Care Med 2000;28:1226-1227.
173. Yocum MW, Butterfield JH, Gharib II: Increased plasma calcitonin levels in systemic mast cell disease. Mayo Clin Proc 1994;69: 987-990.
174. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.